Related Experiment Video

Updated: May 23, 2026

Revealing the Ferroptotic Phenotype of Medulloblastoma
04:01

Revealing the Ferroptotic Phenotype of Medulloblastoma

Published on: March 15, 2024

Deferasirox therapy in children with Fanconi aplastic anemia

Bahattin Tunç1, Betul Tavil, Neslihan Karakurt

  • 1Department of Pediatric Hematology, Ankara Children's Hematology and Oncology Hospital, Diskapi, Ankara/Turkey.

Journal of Pediatric Hematology/Oncology
|April 19, 2012
PubMed

Insights

Deferasirox effectively reduced iron overload in children with Fanconi aplastic anemia (FAA). However, close monitoring for potential kidney and liver toxicity is crucial due to increased risks in this patient group.

Area of Science:

  • Pediatric Hematology
  • Pharmacology
  • Toxicology

Background:

  • Fanconi aplastic anemia (FAA) often leads to transfusional iron overload.
  • Iron chelators are used to manage iron overload, but their use in FAA is not well-documented.
  • Deferasirox is an oral iron chelator with potential application in pediatric patients.

Purpose of the Study:

  • To evaluate the effectiveness and tolerability of deferasirox in children with FAA and transfusional iron overload.
  • To assess the safety profile of deferasirox in this specific pediatric population.

Main Methods:

  • Retrospective follow-up of 39 children with FAA.
  • Analysis of 8 children (20%) treated with deferasirox for transfusional iron overload.
  • Monitoring of serum ferritin levels and assessment of adverse events, including renal and hepatic toxicity.

Main Results:

  • Deferasirox treatment significantly decreased mean serum ferritin levels from 3377 ± 2200 ng/mL to 2274 ± 1300 ng/mL (P<0.05).
  • Common side effects observed were renal toxicity (3 patients) and hepatic toxicity (3 patients).
  • Two patients had peliosis hepatis and two had pre-existing congenital renal abnormalities.

Conclusions:

  • Deferasirox is an effective oral iron chelator for reducing iron overload in children with FAA.
  • Nephrotoxicity and hepatotoxicity were common adverse events in this cohort, differing from gastrointestinal issues seen in other studies.
  • Patients with FAA receiving deferasirox require close monitoring for potential renal and hepatic toxicities, especially those with baseline abnormalities.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...